Obagi Medical: Addresses response by Obagi Board of Directors to its letter says 'Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers' (OMPI) 11.87 : The letter stated "On February 10, 2012, Voce sent a letter to the Obagi Board of Directors criticizing the Board's recent adoption of a poison pill and demanding immediate action to address corporate governance deficiencies and to evaluate strategic alternatives. Voce's letter stated that it believed Obagi has spurned recent overtures to acquire the Company. On February 14, 2012, the Obagi Board responded to Voce's letter. The Board's statement notably did not dispute Voce's claims that the Company had recently received and summarily rebuffed offers to acquire Obagi. In addition, the Obagi Board's response states in part: Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers from this point forward will be reviewed by these independent advisors. Voce believes that this change in Obagi's posture may invite additional acquisition interest....There is substantial strategic interest in an acquisition of Obagi and broad support for a sale of the Company in both the investment and the analyst community. It behooves the Obagi Board to pursue this potential outcome diligently."
